Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform

Date

14 Sep 2024

Session

Poster session 10

Topics

Targeted Therapy;  Cancer Care Equity Principles and Health Economics;  Statistics;  Cancer Epidemiology

Tumour Site

Presenters

Tess Martin

Citation

Annals of Oncology (2024) 35 (suppl_2): S937-S961. 10.1016/annonc/annonc1606

Authors

T. Martin1, A. Bayle2, A. Marabelle3, C.P. Massard4, I. Borget5

Author affiliations

  • 1 Faculty Of Pharmacy - Grades Health Economics Department / Hospital Pharmacy, Paris-Saclay University / AP-HP (Hôpital Européen Georges Pompidou), 91190 - Orsay/FR
  • 2 Office Of Biostatistics And Epidemiology / Inserm Cesp U1018 Oncostat, Labelisé Ligue Contre Le Cancer, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 3 Drug Development Department (ditep) / Inserm U1015 & Cic1428, Gustave Roussy - Cancer Campus / Paris Saclay University, 94805 - Villejuif/FR
  • 4 Drug Development Department (ditep), Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 5 Office Of Biostatistic And Epidemiology / Cesp U1018, Oncostat, Labeled Ligue Contre Le Cancer, Institut Gustave Roussy / Paris Saclay University, 94805 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1549P

Background

In July 2021, France initiated a significant overhaul of the Early Access (EA) process, replacing the former Authorization for Use (ATU) system. This reform aimed to simplify procedures and expedite access to innovative drugs. This study examined the characteristics of oncology (including onco-hematology) drug approvals through the AE process and assessed the methodological quality of clinical trials supporting these requests.

Methods

All oncology applications submitted to the National Health Authority (HAS) since the EA reform (from July 1, 2021) until December 31, 2023 were identified, reviewing approval decisions, timelines, and reasons for acceptance or rejection. The therapeutic class (ATC) of drugs, cancer site and stage were identified, and the data characterizing clinical trials supporting the requests from reviews provided by HAS and clinicaltrial.gov.

Results

Out of 171 EA approvals (including renewal), 88 (51%) were granted for oncologic indications, with evaluation time by HAS of 71 days on average. Excluding renewals, 48 drugs for 53 indications in oncology received EA approval, predominantly monoclonal antibodies or antibody drug conjugates (49%) and CAR-T cell therapies (17%). Most approved indications were in solid oncology (35, 66%), mainly in digestive (23%), urological (23%), or breast cancers (20%), in metastatic indications in the first-line (31%) or second-line (23%). Onco-hematology authorizations accounted for 18 indications (34%), mostly in the third line and beyond (56%). Oncology drugs approved through the EA pathway were primarily backed by phase III trials (70%), including direct comparison (72%) and/or randomization (70%) whereas refused EA drugs were frequently supported by indirect comparison or non-comparative trials (50%). Overall survival (OS) was included as primary or secondary endpoints in 55% of approved EAs, with mature data available in 36% of trials.

Conclusions

The French EA reform has expedited approval across various indications, facilitating access to innovative drugs like monoclonal antibodies or antibody-drug conjugates, notably in solid oncology for metastatic indications. Ensuring high-quality studies is crucial for EA success, with mature data frequently provided.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.